METTL3- and METTL14-mediated m6A modification of SREBF2-AS1 promotes HCC progression and sorafenib resistance [214], while METTL14-dependent m6A methylation similarly induces sorafenib resistance through downregulation of HNF3γ mRNA [144]. The gene discussed is METTL14; the disease is hepatocellular carcinoma.